Loading
A phase 2 trial of ivonescimab in lung cancer, run by Akeso, not yet recruiting.
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment is a phase 2, interventional study registered as NCT07158840 by Akeso, with a registry enrolment figure of 60 participants, started 2025-09-05 and due to reach its primary completion in 2028-09. Interventions recorded: AK112. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Overall response (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC". Sites: China. No results are recorded here; the registry entry is the source.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Akeso, Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.